News

To Treat Over Active Bladder, Medtronic Looks To The Ankle

Medtronic Strikes Deal with Merit Medical Systems to Distribute ViaVerte

Medtronic (NYSE: MDT) announced today that it has signed a distribution agreement with Merit Medical Systems (Nasdaq: MMSI) for the ViaVerte system.

Merit provides the FDA-cleared ViaVerte system, a minimally invasive, implant-free basivertebral nerve ablation (BVNA) technology. According to Medtronic, it is the first and only BVNA system featuring a physician-controlled, steerable mechanism designed for precise targeting of the basivertebral nerve in patients with chronic vertebrogenic lower back pain.

The ViaVerte system enables a minimally invasive, same-day outpatient procedure for chronic pain treatment. By adding a BVNA solution to its portfolio, Medtronic enters into competition with Boston Scientific, which offers the Intracept BVNA system acquired through its 2023 purchase of Relievant Medsystems.

Medtronic stated that the agreement supports its ongoing strategy of pursuing targeted partnerships to strengthen its core business areas. It also builds on its existing relationship with Merit, which currently supplies the Kyphon KyphoFlex unipedicular balloon catheter.

The companies expect to launch the ViaVerte BVNA system later this year.

Paolo Di Vincenzo, president, Medtronic Neuromodulation, said:

“For 50 years, we have advanced how chronic pain is treated,” said Paolo Di Vincenzo, president, Medtronic Neuromodulation, which is part of the Medtronic Neuroscience Portfolio. “Adding ViaVerte basivertebral nerve ablation expands our world-leading pain interventions portfolio and gives patients and their physicians another meaningful option for lasting relief.”

Michael Blackham, EVP, Global OEM, Merit Medical Systems, said:

“We are thrilled to expand our ongoing business relationship with Medtronic by providing Merit’s proprietary articulating technology. We believe ViaVerte represents a significant advancement in the BVNA market.”

Martha G. Aronson, Merit Medical president and CEO, said:

“This agreement underscores our mutual dedication to providing innovative therapies to support physicians and their patients.”

 

© Medtronic PLC

Recent News

Relevance Ventures Leads Multimillion-Dollar Series B Financing for Aqua Medical to Advance Minimally Invasive Type 2 Diabetes Treatment

The Growth of the Medical Industry Amid Tariff Pressures and the Push to Reshore Manufacturing to the United States

Vent Creativity℠ Obtains FDA-Clearance for AI-Powered Digital-Twin Knee Arthroplasty Planning Tool, Hermes.

Johnson & Johnson MedTech Announces Approval of MONARCH™ QUEST for Enhanced Robotic-Assisted Bronchoscopy

Globus Medical obtains FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System

Successful completion of the inaugural shoulder arthroplasty surgeries utilizing Stryker’s Blueprint® Mixed Reality Guidance System occurred at Mayo Clinic in Minnesota and St. Joseph’s Health Care in London, Canada.

Medical Device Technologies Market is projected to increase from USD 4.20 Billion in 2022 to USD 16.32 Billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 18.50% over the forecast period

Hodess Cleanroom Construction expands its cleanroom services capabilities with the acquisitions of Protocol Management Services and Clean Rooms West

Medtronic Will Invest Up to $75 Million And begin Co-Promotion For CathWorks’ FFRangio System In The U.S. Europe and Japan

Tornier Shoulder Arthroplasty Portfolio Introduced by Stryker, With New Tornier Perform Humeral System Launched in Europe